Hello marty
i am trying to get hold of the Sinai people and i emiled pt-rights.org, but NO NO response .
i want to be in the clinical trial.
so why don’t we all participate so we can this forward.
I am sure dad would want to particpate in a trial but from NY to LA for checkups probably isn’t feasible.
Hi y’all,
I’m afraid I don’t know much of anything about those companies myself, & so can’t tell you more about them. You could try putting them into Google to see if anything comes up–that’s what I’d have to do. As far as human trials, those companies are probably no closer than 3-4 years away from that, so there’s probably nothing to sign up for quite yet. They may or may not even be at the point of animal trials yet, and those would come first. It’s great to know that when they do reach the point of needing people to try out the new technology, they should be able to find volunteers!
Hello
Well …I did my homework regarding dr nabil aboras new design of WAK, and found NOTHING in clinical trials. So I contacted the www.pt-rights.org and they faxed me a notice of allowance from egypt patent and trademark office for the design of a new wearable artificial kidney issued in 1997 under his name . Currently the doctor works as a dialysis doctor in Saudi Arabia his Email: maboras@saad.com.sa
i guess you can contact him but if your still interested to get on a clinical trial , you better contact the sinai doctors??
[/quote]
There’s a new article about Home Dialysis Plus–sounds like they’ve made some progress. The link is: http://portland.bizjournals.com/portland/stories/2005/04/25/focus1.html. Here’s the article:
IN DEPTH: HEALTHY LIVING
From the April 22, 2005 print edition (The Business Journal, Portland)
Home dialysis in 2 years?
Wendy Culverwell
Business Journal staff writer
Portland startup Home Dialysis Plus Ltd. is about two years away from marketing a light-weight medical device that will allow patients with failing kidneys to receive dialysis over night in their own homes.
The company is negotiating with potential financial partners and is close to moving from a prototype of its product, code-named “Vera,” to an alpha model.
Too, it is testing its dialyzer technology with a cocktail of human and animal blood instead of the chemical set of the initial tests.
“We’ve made a lot of progress in the 13 months since we announced,” said CEO Michael Baker, who created Home Dialysis Plus with partners Kay Altman and David Browning. The partners specialize in setting up companies around promising technologies.
Home Dialysis Plus is doing much of its own research, but has partnered with Oregon State University on manufacturing technology and the Oregon Nanoscience and Microtechnologies Institute, which has been an advocate for the company.
Baker said the company wants to stay in Portland, though it is talking with potential investors on both coasts.
“We’re very motivated as a management team to grow jobs and infrastructure in Oregon to keep all this at home – no pun intended,” he said.
Home Dialyis Plus isn’t the only startup taking aim at the growing demand.
“There is a race to market for home dialysis,” he agreed.
But, Baker said, his company’s nearest rivals are developing systems that replicate the clinic experience at home. The Home Dialysis Plus is more portable and more oriented to daily treatment.
Diabetes and hypertension are the leading cause of kidney disease, or renal failure. Demand is expected to swamp the existing care system in the coming decade.
There are 450,000 patients in the United States with end-stage renal disease. Of those, an estimated 325,000 to 375,000 are on dialysis. The Centers for Disease Control speculates that those figures will climb past 1 million by 2012.
“The current infrastructure cannot support that kind of growth in a clinic-type environment. The need for a home type product is huge,” said Baker, who estimates that between 25 and 35 percent of dialysis patients will benefit from home-based treatment.
Like another innovation in the care of diabetes, the insulin pump, the dialysis-at-home model offers more than convenience. It has the potential to improve the patient’s quality of life by mimicking the body’s natural rhythms better than current therapies. Home Dialysis Plus will work over night, at a more relaxed pace than the thrice-weekly sessions that can take up to four hours at dialysis centers.
That offers a number of benefits for patients, Baker said. Daily treatment can avoid some of the chemical complications that lead to heart problems for patients who depend on clinic-based dialysis. It does a better job of cleansing the patient’s blood, meaning in-home patients face less restrictive diets and don’t need to attend to their fluid levels as scrupulously as patients treated in clinics.
“Our treatment will reduce the amount of adjunct medications people will need,” Baker said. “We enhance it even further because of the efficiencies of our dialyzer filter.”
Baker and his partners believe the company will generate at least 600 jobs as the demand grows. The current market for dialysis equipment is worth $400 million.
Baker said it’s only fitting that Home Dialysis Plus expand in its hometown – the home of kidney dialysis in the first place. Dr. Richard Drake, who is on the Home Dialysis Plus board, invented the popular Drake Willock dialysis machine in the 1960s and formed a company, DWS Inc., to produce it. Now retired, he sold DWS Inc. in the 1970s.
Baker likes to think Home Dialysis Plus is layering new technology on a life-saving treatment.
“We’re doing a do-over. We’re doing it using modern technologies,” Baker said.
About the size of a suitcase, “Vera” will weigh about 30 pounds and will deliver treatments comparable in cost with reimbursement rates under Medicare, which covers dialysis for all patients.
That is an important consideration for the company’s business model, Baker said.
“This fits into the current Medicare and Medicaid funding program,” Baker said, adding that private insurers, led by Aetna, have indicated support for home treatment.
“It reduces the cost of supporting that patient in the global sense and it enhances their quality of life,” he said.
Home Dialysis Plus researchers named their device for a colleague’s mother, who died after suffering from renal failure.
Contact Wendy Culverwell at wculverwell@bizjournals.com or 503-219-3415.
New info on Biophiltre…
Biophiltre
330 Beach Rd.
Burlingame, CA 94010
1-650-227-7777
www.biophiltre.com
Founded: 2004
CEO: Co-founders Gayle Pergamit and Martin Edelstein
Employees: N/A
Funding: N/A
Key Investors: Privately funded
Biophiltre, which is bootstrapping without VC funding, is using techniques first discovered at the University of Michigan to develop filtration technologies modeled on cell membranes. The first application will be tiny “renospheres” that, when injected into the bloodstream, could filter waste, potentially eliminating the need for artificial kidney dialysis—the project is already in early-phase FDA trials. The Biophiltre team’s likely next project will be with sister company Agua Via, using the same underlying technology to compete in the crowded segment of nanotech water purification. The company’s decision to forgo VC investment takes guts; futurist author Ms. Pergamit and biochemist Dr. Edelstein are unproven in commercializing nanotechnology
There’s also a video clip of one of the founders talking about her product. Click on the photo to make the video come up:
http://nanotech2004.thenewatlantis.com/2004/10/nano_and_kidney.html
Thanks Manal,
I managed to contact dr nabil aboras kawalit.
His group finished the design and they submitted their article for publication.
I think they have the solution.
[/quote][/quote]
Hmm, this is just insanely amazing!!! But, BUT…hmmm would it really work? Nano Technology is a buzz word almost everywhere…
Sounds very promising though…
just imagine, those tiny robots inside your body cleaning you 24x a day!! However, where the heck will the waste go? And once these tiny Nanos are injecte into you I wonder how long they last…
Good questions Gus. And how do you get the fluid out? The other issue for “wearable” versions is how do you access the blood?
Hi y’all,
Home Dialysis Plus just put out a press release about some funding they received:
[b]FOR IMMEDIATE RELEASE
Release Source:
Michael Baker, CEO
Home Dialysis Plus, Ltd[/b]
971.563.3083 direct
503.961.8545 fax
$170,000 Gap Fund Awarded to OSU to Support the Commercialization of a Revolutionary Home Hemodialysis Unit
PORTLAND, OR —JANUARY 3, 2006 — Home Dialysis Plus, Limited (HD+) announces an award of $170,000 to fund the development of a prototype for a home hemodialysis machine using microtechnology. The Microtechnology-based Energy and Chemical Systems (MECS) technology, co-patented by HD+ and Oregon State University, will enable the creation of a unique and portable hemodialysis unit that allows patients the freedom to seek improved treatment from kidney failure in the comfort of their own homes.**
The portable, suitcase-sized HD+ hemodialysis machine will allow patients to dialyze at home for up to 8 hours while they sleep. This significantly longer, slower filtration method simulates natural kidney function much more closely than most dialysis treatments currently done in dialysis centers. Additionally, blood damage, use of medications, and hospitalizations will be dramatically reduced. The HD+ System will use ordinary tap water and electrical outlets, making it truly patient.
The Gap Fund awarded by Oregon Nanoscience and Microtechnologies Institute (ONAMI) to Oregon State University’s College of Engineering will allow OSU to support the commercialization of the HD+ MECS dialyzers (artificial kidney filters). Beginning January 1st, OSU/HD+ Engineers will begin using the $170,000 to scale-up, test and begin development of high–volume fabrication processes for the full-sized MECS dialyzers.*
“ONAMI is delighted to be a part of commercializing an entirely new type of microtechnology in the high-impact field of medical devices, and in an area that promises enormous social benefit”, says Skip Rung, President and Executive Director of ONAMI. “Oregon industry’s vast experience with microproducts R&D and high-volume manufacturing make it the ideal place to build this business.”
There are currently 450,000 patients in the United States with end-stage renal disease (ESRD). With skyrocketing levels of type 2 diabetes and hypertension as the leading causes of kidney failure, the Center for Disease Control estimates that the number of U.S. ESRD patients will exceed 1 million by 2012.*
The most recent statistics from the United States Renal Data System show that the average cost of providing care for in-center hemodialysis patients is $68,000 (2004 data). Jim Curtis, Director of Clinical Services for HD+, notes, “with studies showing savings of 15% in the overall cost of care with daily home hemodialysis therapy, the potential savings to Medicare could easily exceed $3 billion dollars a year.”**
“The demographics are getting hard to ignore,” says Dori Schatell, Executive Director of the Medical Education Institute since 2001 (http://www.homedialysis.org). “There are more dialysis patients than ever before, with fewer nurses and nephrologists to care for them. With virtually every other aspect of health care being done at home, it only makes sense that we change the way we deliver dialysis care as well.” Schatell hopes to some day see 50% of patients receiving care at home, as opposed to the current number of less than 8%. Recognizing that HD+ offers a smaller, more portable machine, Schatell favors the idea of “giving patients more options.”
Completion of a full-size working dialyzer prototype is expected to be announced August, 2007. HD+ currently seeks outside funding for the development and manufacturing of the unit, which could be ready for market as early as 2008.
HOME DIALYSIS PLUS, a Portland, Oregon based company is focused on advancing the MECS dialyzer technology. The company aims to produce patient-friendly, home hemodialysis treatment options that offer improved health outcomes. Michael Baker, CEO <mailto:homedialysisplus@hotmail.com>homedialysisplus@hotmail.com*or <mailto:michael@bakercgroup.com>michael@bakercgroup.com
The OSU - MECS Initiative is an interdisciplinary program of Oregon State University, currently involving the colleges of Agriculture, Engineering and Science.* Microtechnology-based Energy and Chemical Systems (MECS) involve the miniaturization of devices that deal with heat transfer, mass transfer and fluidic processes. Examples of MECS technology include miniature heat pumps, chemical synthesis systems, waste cleanup devices, miniature power sources and bio-reactors. http://mecs.oregonstate.edu Kevin Drost, Director: drost@engr.orst.edu
ONAMI, the Oregon Nanoscience and Microtechnologies Institute, is Oregon’s first Signature Research Center. A cooperative venture among the State of Oregon government and world-class nanoscience and microtechnology R&D institutions and industry in the Northwest, ONAMI was created to grow, research and accelerate commercialization to advance Oregon’s leading economic sector and expand the benefits of technology innovation to traditional and natural resource industries. http://www.onami.us Skip Rung, President and Executive Director: skip@onami.us
[quote=Dori Schatell;11826]Hi y’all,
Home Dialysis Plus just put out a press release about some funding they received:
[B]FOR IMMEDIATE RELEASE
Release Source:
Michael Baker, CEO
Home Dialysis Plus, Ltd[/B]
971.563.3083 direct
503.961.8545 fax
$170,000 Gap Fund Awarded to OSU to Support the Commercialization of a Revolutionary Home Hemodialysis Unit
PORTLAND, OR —JANUARY 3, 2006 — Home Dialysis Plus, Limited (HD+) announces an award of $170,000 to fund the development of a prototype for a home hemodialysis machine using microtechnology. The Microtechnology-based Energy and Chemical Systems (MECS) technology, co-patented by HD+ and Oregon State University, will enable the creation of a unique and portable hemodialysis unit that allows patients the freedom to seek improved treatment from kidney failure in the comfort of their own homes.**
The portable, suitcase-sized HD+ hemodialysis machine will allow patients to dialyze at home for up to 8 hours while they sleep. This significantly longer, slower filtration method simulates natural kidney function much more closely than most dialysis treatments currently done in dialysis centers. Additionally, blood damage, use of medications, and hospitalizations will be dramatically reduced. The HD+ System will use ordinary tap water and electrical outlets, making it truly patient.
The Gap Fund awarded by Oregon Nanoscience and Microtechnologies Institute (ONAMI) to Oregon State University’s College of Engineering will allow OSU to support the commercialization of the HD+ MECS dialyzers (artificial kidney filters). Beginning January 1st, OSU/HD+ Engineers will begin using the $170,000 to scale-up, test and begin development of high–volume fabrication processes for the full-sized MECS dialyzers.*
“ONAMI is delighted to be a part of commercializing an entirely new type of microtechnology in the high-impact field of medical devices, and in an area that promises enormous social benefit”, says Skip Rung, President and Executive Director of ONAMI. “Oregon industry’s vast experience with microproducts R&D and high-volume manufacturing make it the ideal place to build this business.”
There are currently 450,000 patients in the United States with end-stage renal disease (ESRD). With skyrocketing levels of type 2 diabetes and hypertension as the leading causes of kidney failure, the Center for Disease Control estimates that the number of U.S. ESRD patients will exceed 1 million by 2012.*
The most recent statistics from the United States Renal Data System show that the average cost of providing care for in-center hemodialysis patients is $68,000 (2004 data). Jim Curtis, Director of Clinical Services for HD+, notes, “with studies showing savings of 15% in the overall cost of care with daily home hemodialysis therapy, the potential savings to Medicare could easily exceed $3 billion dollars a year.”**
“The demographics are getting hard to ignore,” says Dori Schatell, Executive Director of the Medical Education Institute since 2001 (http://www.homedialysis.org). “There are more dialysis patients than ever before, with fewer nurses and nephrologists to care for them. With virtually every other aspect of health care being done at home, it only makes sense that we change the way we deliver dialysis care as well.” Schatell hopes to some day see 50% of patients receiving care at home, as opposed to the current number of less than 8%. Recognizing that HD+ offers a smaller, more portable machine, Schatell favors the idea of “giving patients more options.”
Completion of a full-size working dialyzer prototype is expected to be announced August, 2007. HD+ currently seeks outside funding for the development and manufacturing of the unit, which could be ready for market as early as 2008.
HOME DIALYSIS PLUS, a Portland, Oregon based company is focused on advancing the MECS dialyzer technology. The company aims to produce patient-friendly, home hemodialysis treatment options that offer improved health outcomes. Michael Baker, CEO <mailto:homedialysisplus@hotmail.com>homedialysisplus@hotmail.com*or <mailto:michael@bakercgroup.com>michael@bakercgroup.com
The OSU - MECS Initiative is an interdisciplinary program of Oregon State University, currently involving the colleges of Agriculture, Engineering and Science.* Microtechnology-based Energy and Chemical Systems (MECS) involve the miniaturization of devices that deal with heat transfer, mass transfer and fluidic processes. Examples of MECS technology include miniature heat pumps, chemical synthesis systems, waste cleanup devices, miniature power sources and bio-reactors. http://mecs.oregonstate.edu Kevin Drost, Director: drost@engr.orst.edu
ONAMI, the Oregon Nanoscience and Microtechnologies Institute, is Oregon’s first Signature Research Center. A cooperative venture among the State of Oregon government and world-class nanoscience and microtechnology R&D institutions and industry in the Northwest, ONAMI was created to grow, research and accelerate commercialization to advance Oregon’s leading economic sector and expand the benefits of technology innovation to traditional and natural resource industries. http://www.onami.us Skip Rung, President and Executive Director: skip@onami.us[/quote]
Oh my gawd, YES!! The whole idea is about home and best of all is that it should be small! That’s what we want at home, small dialysis devices! Hurray!!
[B]“Think Small”!
[/B]Dori, thanks for this update!
Hi y’all. Wait 'til you see how small the dialyzer is going to be! There’s an on-line interview at: <http://www.kval.com/news/5349746.html?video=pop&t=a>http://www.kval.com/news/5349746.html?video=pop&t=a.
Oh yeah–there’s a 10-second ad about truck liners that plays first. Must be their deal with the hosting site.
A treatment for polycystic kidney disease(PKD), a leading cause of fatal kidney failure worldwide, has been identified by a research team led by Yale biochemist Craig Crews, according to a report in the Proceedings of the National Academy of Sciences.
Over 12 million people worldwide suffer from PKD, a genetic disorder that causes uncontrolled growth of cells lining tubules in the kidneys, and results in the formation of many, large fluid-filled cysts in the kidneys.
http://www.pt-rights.org/en/news_details.php?id=38
A Potential Drug for Polycystic Kidney Disease
The International Renal Care Group annual meeting, held in Athens, Greece (January 15, 2008) presented the newest advances in basic and clinical nephrology science. Several presentations and symposia discussed the clinical outcomes of polycystic kidney disease recent trials
“Decades of clinical and basic studies by NIH and others have delivered this exciting opportunity for translational research,” says Carlo Martinez, M.D., a kidney specialist from the USA who directs the Polycystic Kidney Disease- International Renal Care Group
Dr Spiros Caviars discussed the OPC31260 and related drugs that are currently being tested as possible treatments for conditions that cause water retention, such as heart or liver failure, demonstrating the drug’s safety.
“The fact that these drugs selectively target specific receptors on these kidney cells and bypass other organs makes them relatively nontoxic and adds to their value as a potential treatment for polycystic kidney disease,” says Issa Kawalit , M.D, member of the board of directors of the International Renal Care Group